See more : Hefei Department Store Group Co.,Ltd (000417.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Alector, Inc. (ALEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alector, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Data Storage Corporation (DTST) Income Statement Analysis – Financial Results
- Iron Mountain Incorporated (0JDP.L) Income Statement Analysis – Financial Results
- PT Indofarma Tbk (INAF.JK) Income Statement Analysis – Financial Results
- Shreevatsaa Finance and Leasing Limited (SHVFL.BO) Income Statement Analysis – Financial Results
- Changchun FAWAY Automobile Components Co.,Ltd (600742.SS) Income Statement Analysis – Financial Results
Alector, Inc. (ALEC)
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 97.06M | 133.62M | 207.09M | 21.10M | 21.22M | 27.68M | 3.74M | 416.00K |
| Cost of Revenue | 192.12M | 8.47M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| Gross Profit | -95.05M | 125.15M | 17.68M | -135.77M | -79.31M | -45.35M | -26.18M | -13.26M |
| Gross Profit Ratio | -97.93% | 93.66% | 8.54% | -643.53% | -373.76% | -163.87% | -700.83% | -3,187.02% |
| Research & Development | 192.12M | 210.42M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| General & Administrative | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Other Expenses | 0.00 | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Operating Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Cost & Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.85M | 8.47M | 8.31M | 7.27M | 5.57M | 1.02M | 680.00K | 201.00K |
| EBITDA | -142.89M | -129.36M | -29.05M | -187.91M | -109.47M | -56.27M | -32.00M | -14.93M |
| EBITDA Ratio | -147.22% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -856.73% | -3,589.18% |
| Operating Income | -151.74M | -137.83M | -37.36M | -195.17M | -114.40M | -57.29M | -32.68M | -15.13M |
| Operating Income Ratio | -156.33% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -874.94% | -3,637.50% |
| Total Other Income/Expenses | 26.56M | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Income Before Tax | -125.18M | -130.06M | -36.33M | -190.23M | -105.39M | -52.25M | -32.48M | -15.11M |
| Income Before Tax Ratio | -128.97% | -97.33% | -17.54% | -901.64% | -496.65% | -188.78% | -869.61% | -3,632.21% |
| Income Tax Expense | 5.21M | 3.25M | -8.32M | -7.27M | -5.57M | 5.04M | 0.00 | 0.00 |
| Net Income | -130.39M | -133.31M | -28.01M | -182.96M | -99.81M | -52.25M | -32.48M | -15.11M |
| Net Income Ratio | -134.34% | -99.77% | -13.53% | -867.21% | -470.39% | -188.78% | -869.61% | -3,632.21% |
| EPS | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| EPS Diluted | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| Weighted Avg Shares Out | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
| Weighted Avg Shares Out (Dil) | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting
Alector: The GSK Deal Is A Major Value Add
Alector Announces Appointment of Elizabeth A. Garofalo, M.D.
Why Alector Shares Are Diving Today
Alector Provides Executive Leadership Update
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
Alector Reports Second Quarter 2021 Financial Results
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients
Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation
Source: https://incomestatements.info
Category: Stock Reports